Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome

We have found that, in addition to Bcl-2 and Bax, the expression levels of apoptosis inducers (Bad, Bak) and inhibitors (Bcl-xL, Mcl-1) were highly variable in blasts from 78 children with newly diagnosed acute lymphoblastic leukemia (ALL). The patients were enrolled in the national study ALL-7 of the Dutch Childhood Leukemia Study Group. In contrast to Bcl-2 that inversely correlated with %S-phase cells and WBC, and was lower in T than in B-lineage ALL, the Bcl-2 family members were not found to be associated with features at presentation. These expression levels were also compared with drug resistance in in vitro MTT (methyl-thiazol-tetrazolium) assays for prednisolone, vincristine and asparaginase in 46 children. Protein expression levels of the Bcl-2 family were not found to correlate with in vitroresistance to the individual drugs or the combined drug resistance profile. In addition, neither peripheral blast reduction after 1 week of prednisone monotherapy nor long-term disease-free interval or survival showed a correlation with protein expression. Our results indicate that the anti-proliferative function of Bcl-2 dominates its anti-apoptotic function in ALL, but neither Bcl-2 nor the Bcl-2 family members gained prognostic information in the risk-adapted protocol ALL-7.

[1]  F. Behm,et al.  Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. , 1996, Blood.

[2]  H. Katz.  bcl-2 protein in non-small-cell lung carcinoma. , 1994, The New England journal of medicine.

[3]  L. Smets,et al.  Involvement of the glucocorticoid receptor in stress-induced apoptosis of leukemic cells , 1998, Leukemia.

[4]  W. Kamps,et al.  DNA index and %S-phase cells determined in acute lymphoblastic leukemia of children: a report from studies ALL V, ALL VI, and ALL VII (1979-1991) of the Dutch Childhood Leukemia Study Group and The Netherlands Workgroup on Cancer Genetics and Cytogenetics. , 1995, Medical and pediatric oncology.

[5]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[6]  H. Findley,et al.  Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. , 1997, Blood.

[7]  L. Smets,et al.  Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells. , 1996, Leukemia & lymphoma.

[8]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[9]  John Calvin Reed,et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. , 1998, Blood.

[10]  W. Hiddemann,et al.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.

[11]  A. Hart,et al.  The Baxα:Bcl‐2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia , 1997, International journal of cancer.

[12]  C. Borner.  Diminished Cell Proliferation Associated with the Death-protective Activity of Bcl-2* , 1996, The Journal of Biological Chemistry.

[13]  L. Gordon,et al.  BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. , 1998, Blood.

[14]  A. Berns,et al.  T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage‐induced cell death in the absence of p53. , 1996, The EMBO journal.

[15]  R. Pieters,et al.  In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia , 1997 .

[16]  R. Kofler,et al.  Splice site mutation in the glucocorticoid receptor gene causes resistance to glucocorticoid-induced apoptosis in a human acute leukemic cell line. , 1995, Cancer research.

[17]  D.,et al.  Regression Models and Life-Tables , 2022 .

[18]  K. Kinzler,et al.  Paradoxical inhibition of solid tumor cell growth by bcl2. , 1994, Cancer research.

[19]  R. Pieters,et al.  Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. , 1998, Blood.

[20]  H. Sather,et al.  Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study , 1997 .

[21]  H. Petrie,et al.  Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death , 1996, The Journal of experimental medicine.

[22]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[23]  Z. Oltvai,et al.  Checkpoints of dueling dimers foil death wishes , 1994, Cell.

[24]  C. Pui,et al.  Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia , 1997, Current opinion in hematology.

[25]  John Calvin Reed.  Bcl-2: prevention of apoptosis as a mechanism of drug resistance. , 1995, Hematology/oncology clinics of North America.

[26]  G. Gil-Gómez,et al.  Bax alpha perturbs T cell development and affects cell cycle entry of T cells. , 1996, The EMBO journal.

[27]  L. Smets,et al.  BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. , 1994, Blood.

[28]  Z. Oltvai,et al.  Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. , 1993, Seminars in cancer biology.

[29]  A. Hagemeijer,et al.  Update of the cytogenetic study of childhood non-high-risk acute lymphocytic leukemia at diagnosis in protocol VI of the Dutch Childhood Leukemia Study Group. , 1990, Haematology and blood transfusion.

[30]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[31]  J. Lee,et al.  bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. , 1995, Cancer research.

[32]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[33]  A. Strasser,et al.  The cell death inhibitor Bcl‐2 and its homologues influence control of cell cycle entry. , 1996, The EMBO journal.

[34]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. Linette,et al.  Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.